Risks of parenteral deferoxamine for acute iron poisoning

Clinical Toxicology

Volumn 34, Issue 5, 1996, Pages 491-497

  Howland, Mary Ann ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON;

CONFERENCE PAPER; DRUG SAFETY; EYE TOXICITY; HUMAN; HYPOTENSION; INFECTION; IRON OVERLOAD; LUNG TOXICITY; OTOTOXICITY; RISK BENEFIT ANALYSIS; TOXICOKINETICS;

ADMINISTRATION, ORAL; ANTIDOTES; COMMUNICABLE DISEASES; DEFEROXAMINE; EAR DISEASES; EYE DISEASES; HUMANS; HYPOTENSION; INJECTIONS, INTRAVENOUS; IRON; POISONING; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK ASSESSMENT;

EID: 0029825981     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563659609028006     Document Type: Review

References (50)

1. Reissmann KR, Coleman TJ, Budai BS, et al. Acute intestinal iron intoxication 1. Iron absorption, serum iron and autopsy findings. Blood 1955;10:35-45.
2. Vernon DD, Banner W Jr, Dean IM. Hemodynamic effects of experimental iron poisoning. Ann Emerg Med 1989;18:863-866.
3. Whitten CF, Chen YC, Gibson GW. Studies in acute iron poisoning HI: The hemodynamic alterations in acute experimental iron poisoning. Ped Res 1968;2:479-485.
4. Leikin S, Vossough P, Mochiv-Fatemi F. Chelation therapy in acute iron poisoning. J Peds 1969;71:425-430.
5. Douglas D, Smilkstein M. Deferoxamine-ironinduced pulmonary injury and Nacetylcysteine. J Toxicol Clin Toxicol 1995, 33:495.
6. Fontecave M, Pierre JL. Iron: metabolism, toxicity and therapy. Biochimie 1993;75:767-773.
7. Hersho C, Weatherall D. Iron chelating therapy. CRC Rev in Oin Lab Sci 1988;26:303-345.
8. Aust SD, Chignell CF, Bray TM, Kalyanaraman B, Mason RP. Contemporary issues in toxicology. Free radicals in toxicology. Toxicol Appl Pharmacol 1993;120:168-178.
9. Halliwell B. Protection against tissue damage in vivo by desferrroxamine: What is its mechanism of action? Free Radic Biol Med 1989;7:645-651.
10. Halliwell B, Gutteridge JMC. Role of iron in oxygen radical reactions. Methods Enzymol 1984;105:47-56.
11. Ryan TP, Aust SD. The role of iron in oxygen mediated toxicities. Crit Rev Toxicol 1992;22: 119-141.
12. Keberle H. The biochemistry of deferoxanine and its relation to iron metabolism. Ann NY Acad Sci 1964;119:758-768.
13. Peters G, Keberle K, Schmid K, Brunner H. Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and rat. Biochem Pharmacol 1966;15:93-109.
14. Lee P, Mohammed N, Marshal L, et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos 1993;21: 640-644.
15. Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 1979;42:547-555.
16. Whitten CF, Gibson G, Good K, et al. Studies in acute iron poisoning II: Desferioxamine in the treatment of acute iron poisoning. Clinical observations, experimental studies, and theoretical considerations. Peds 1965;36:322-325.
17. Whitten CF, Chen YC, Gibson GW. Studies in acute iron poisoning II: Further observations of desferoxamine in the treatment of acute experimental iron poisoning. Peds 1966;38:102-110.
18. Westlin WE. Deferoxamine in the treatment of acute iron poisoning. Clinical experiences with 172 children. Clin Pediatr Phila 1966;5:531-535.
19. Tenenbein M, Kowalski S, Shenko A, Bowden DH, Adamson IY. Pulmonary toxic effects of continuous desferrioxamine adminstration in acute iron poisoning. Lancet 1992;339:699-701.
20. Isselbacher KJ, Braunwald E, Wilson JD, et al. Harrison's Principles of Internal Medicine. New York: McGraw-Hill 1994:1240.
21. Thompson 7. Two cases of ferrous sulfate poisoning. Brit Med J 1947;U640.
22. Foucar M Gordon B, Kaye S. Death foliovang ingestion of ferrous sulfate. Am J Clin Path 1948;18:971-973.
23. Clark WK Jurow SS, Walford RL, Warthen RO. Ferrous sulfate poisoning. AMA Am J Dis Child 1952;220-226.
24. Lieut Branch. Ferrous sulfate poisoning - Report of a fatal case. Peds 1952;10:677-680.
25. Duffy TL, Diehl AM. Report of three cases. J Peds 1952;40:1-5.
26. Luongo MA, Bjomson SS. The liver in ferrous sulfate poisoning. A report of three fatal cases in children and an experimental study. N Engl J Med 1954;251:995-999.
27. Hoppe J, Marcelli G, Taintenn M. A review of the toxicity of iron compounds. Am J Med Sci 1955;558-571.
28. Freedman MH, Grisaru D, Olivieri N, Mac Lusky I, Thorner PS. Pulmonary syndrome in patients vath thalessemiamajorreceivingintravenousdeferroxamine indusions. Am J Dis Child 1990;144:565-569.
29. Castriota Scanderberg A, Izzi GC, Buttufini A, Benaglia G. Pulmonary syndrome and intravenous high-dose desferoxamine. Lancet 1990;336:1511.
30. Anderson KJ, Rivers RPA. Desferoxamine in acute iron poisoning. Lancet 1992;339:1602.
31. Weitman S, Buchanan G, Karnen B. Pulmonary toxicity of deferroxamine in children with advanced cancer. J Natl Cancer Inst 1991;83:1834-1835.
32. Miller Y, Rosenwasser L, Bessette J, et al. Rapid desensitisation for desferrioxarnine anaphylactic reaction. Lancet 1981 ;i: 1059.
33. Helson L, Helson C, Braverman S, Deb G,. Donfrancesco A. Desferrioxarnine in acute iron poisoning. Lancet 1992;339:1602-1603.
34. Adamson IY, Sienko A, Tenenbein M. Pulmonary toxicity of deferoxamine in iron-poisoned mice. Toxicol Appl Pharmacol 1993;120:13-19.
35. Davies S, Hungerford J, Arden G, et al. Ocular toxicity of high dose intravenous desferrioxarnine. Lancet 1983;ii: 181-184.
36. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986;314:869-873.
37. Pengloan J, Dantal J, Rossazza K, Abazza M, Nivet H. Ocular toxicity after a single dose of desferrioxarnine in two hemodialyzed patients. Nephron 1987;46:211-212.
38. Bene C, Manzler A, Bene D, Kranias G. Irreversible ocular toxicity from single "challenge" dose of deferoxamine. Clin Nephron 1989;31:45-48.
39. Blake DR, Winyard P, Lunec J, et al. Cerebral and ocular toxicity induced by dexferrioxamine. Q J Med 1985;219:345-355.
40. Porter J, Jaswon M, Huehns E, et al. Desferrioxarnine ototoxicity: evaluation of risk factors in thallessemic patients and guidelines for safe dosage. Br J Haematol 1989;73:403-409.
41. Simon P, Ang KS, Meyrier A, Allain P, Mauras Y. Desferrioxarnine, ocular toxicity and trace metals. Lancet 1983; ii:512-513.
42. Pall H, Blake DR, Winyard P, et al. Ocular toxicity of desferrioxarnine - an example of copper promoted auto-oxidative damage? Br J Ophthalmol 1989;73: 42-47.
43. Gerhlbach PL, Purple RL, Hallaway PE, Hedlund BE. Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model. Invest Ophthalmol Vis Sci 1993;34:2871-2877.
44. Melby K, Slordahl S, Gutteberg T, Nordbo SA. Septicaemia due to Yersinia enterocolitica after oral overdsoe of iron. Br Med J Clin Res Ed 1982;285: 467-468.
45. Mofenson HC, Caraccio TR, Sharieff N. Iron sepsis: Yersinia enterocolitica septicemia possibly caused by an overdose of iron. N Engl J Med 1987;316: 1092-1093.
46. Robins-Browne RM, Prpic JK. Effects of iron and desferrioxarnine on infections with Yersinia enterocolitica. Infect Immun 1985;47:774-779.
47. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993;91:1979-1986.
48. Bentur Y, McGuigan M, Koren G, G. Deferoxamine (desferroxamine), new toxicities for an old drug. Drug Saf 1991;6:37-46.
49. Proppei R, Shurm S, Nathan D. Reassessment of the use of deferrioxamine B in iron overload. N Engl J Med 1976;294:1421-1423.
50. Cheney K, Gumbiner C, Benson B. Tenenbein M. Survival after a severe iron poisoning treated with intermittent infusions of deferoxamine. J Toxicol Clin Toxicol 1995;33:61-66.